MP Healthcare Venture Management
Home About Us Portfolio News Contact
HomeAbout UsPortfolioNewsContact
MP Healthcare Venture Management
Draupnir Bio completes €12 million seed round to progress development of oral small molecule degraders of extracellular proteins
Guest UserJuly 17, 2024
Facebook0 Twitter LinkedIn0 Reddit 0 Likes
Previous

Blacksmith Medicines Granted U.S. Patent Covering Antibacterial Compounds Targeting LpxC

Guest UserJuly 3, 2025
Next

PharmEnable Therapeutics and Sosei Heptares Expand Drug Discovery Collaboration

Guest UserOctober 11, 2023

© 2010-2025 MP Healthcare Venture Management, Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

About UsPortfolioNews Contact